Search
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. … [A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes.
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis … [A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA … Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Disulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalA carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.
Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersSynonyms: N,N,N',N'-tetraethylthiuram disulfide, 1,1'-dithiobis(N,N-diethylthioformamide)Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approved(From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) … In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative.
Categories: Compounds used in a research, industrial, or household settingGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … [L39855] High-dose [methotrexate], an antifolate agent, has been widely and safely used for many decades in treating various cancers; however, even with aggressive hydration, urine alkalinization, and
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis. … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.
Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDESpesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalin December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … Spesolimab is an interleukin-36 (IL-36) receptor antagonist.